Aficamten: Potentially Groundbreaking Treatment for Nonobstructive HCM
Aficamten shows potential to be the first FDA-approved treatment for nonobstructive HCM, as reported by Cardiovascular Business.
Aficamten shows potential to be the first FDA-approved treatment for nonobstructive HCM, as reported by Cardiovascular Business.